NFKB1 and Miyoshi myopathy: Activation of NF-κB by bortezomib may be repressed by tumor necrosis factor receptor super family member 18 (TNFRSF18, also called GITR) in MM cells through the suppression of NF-κB translocation to the cell nucleus (Hideshima et al., 2009).